To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older
Public ClinicalTrials.gov record NCT00082095. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label Trial Comparing Treatment With Either Pegylated Liposomal Doxorubicin or Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer in Women 60 Years and Older
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to compare treatment with either pegylated liposomal doxorubicin or capecitabine as first line chemotherapy for metastatic breast cancer in women 60 years and older.
Study identification
- NCT ID
- NCT00082095
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 62 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2004
- Primary completion
- Nov 30, 2005
- Completion
- Nov 30, 2005
- Last update posted
- Oct 8, 2014
2004 – 2005
United States locations
- U.S. sites
- 27
- U.S. states
- 19
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Fountain Valley | California | — | — |
| Not listed | Oxnard | California | — | — |
| Not listed | Soquel | California | — | — |
| Not listed | Boca Raton | Florida | — | — |
| Not listed | New Port Richey | Florida | — | — |
| Not listed | Plantation | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Springfield | Illinois | — | — |
| Not listed | Hazard | Kentucky | — | — |
| Not listed | Shreveport | Louisiana | — | — |
| Not listed | Scarborough | Maine | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Clinton Township | Michigan | — | — |
| Not listed | Saint Louis Park | Minnesota | — | — |
| Not listed | Lebanon | New Hampshire | — | — |
| Not listed | Voorhees Township | New Jersey | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Armonk | New York | — | — |
| Not listed | New City | New York | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Fredericksburg | Texas | — | — |
| Not listed | Burlington | Vermont | — | — |
| Not listed | Colchester | Vermont | — | — |
| Not listed | Everett | Washington | — | — |
| Not listed | Vancouver | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00082095, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 8, 2014 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00082095 live on ClinicalTrials.gov.